not tagged
not tagged
['crpc']
 for pts w/ #mcrpc and pathogenic atm alteration (germline/somatic) +progression after 1 line of ar pathway inhibitor, do you recommend tx w/ a parp inhibitor? if you voted no, pls share your thoughts, why not consider a parp inhibitor in this situation? #apccc22 #asco22
The APCCC provides a forum to discuss and debate current questions on the clinical management of men with advanced prostate cancer. Follow #APCCC22